Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) EPS (Weighted Average and Diluted) (2020 - 2025)

KalVista Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 4 years, with the latest figure at -$0.99 for Q2 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 7.48% to -$0.99 in Q2 2025 year-over-year; TTM through Apr 2025 was -$3.84, a 11.3% decrease, with the full-year FY2025 number at -$3.69, down 7.27% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.99 in Q2 2025 for KalVista Pharmaceuticals, down from -$0.91 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for KALV hit a ceiling of -$0.74 in Q3 2023 and a floor of -$1.07 in Q2 2024.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$0.89 across 3 years, with a median of -$0.87 in 2024.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): fell 17.57% in 2024 and later increased 7.48% in 2025.
  • Tracing KALV's EPS (Weighted Average and Diluted) over 3 years: stood at -$0.8 in 2023, then dropped by 13.75% to -$0.91 in 2024, then fell by 8.79% to -$0.99 in 2025.
  • Business Quant data shows EPS (Weighted Average and Diluted) for KALV at -$0.99 in Q2 2025, -$0.91 in Q4 2024, and -$0.87 in Q3 2024.